Cross-Reactive Donor-Specific CD8⁺ Tregs Efficiently Prevent Transplant Rejection

Area of Science:

• Immunology
• Transplantation Biology
• Molecular Medicine

Background:

• Current transplant therapies rely on broad immunosuppression, which carries significant risks.
• Developing antigen-specific tolerance is crucial to minimize side effects and improve long-term graft survival.
• Identifying natural antigens recognized by regulatory T cells (Tregs) is key to achieving this specificity.

Purpose of the Study:

• To identify natural antigens recognized by regulatory T cells (Tregs) in the context of transplantation.
• To explore the potential of these identified antigens in inducing antigen-specific transplant tolerance.
• To investigate the role of CD8+ Tregs in graft acceptance and rejection.

Main Methods:

• Identification of conserved 7-amino acid consensus sequences within MHC class II molecules.
• Characterization of epitopes recognized by cross-reactive CD8+ Tregs.
• In vivo induction of antigen-specific Tregs using a 16-amino acid peptide.
• Testing the efficacy of human HLA-derived peptides in activating human CD8+ Tregs.

Main Results:

• Discovery of shared 7-amino acid consensus sequences in MHC class II-derived epitopes recognized by CD8+ Tregs.
• Demonstration that these CD8+ Tregs are enriched within the graft.
• Successful induction of transplant tolerance in vivo using a specific 16-amino acid peptide.
• Evidence that human HLA class II-derived peptides can activate human CD8+ Tregs.

Conclusions:

• Specific peptide epitopes derived from MHC molecules can be recognized by CD8+ Tregs.
• Antigen-specific CD8+ Tregs can be therapeutically induced to promote transplant tolerance.
• This research provides a foundation for developing novel peptide-based immunotherapies for transplantation.
• Understanding CD8+ Treg recognition mechanisms is vital for advancing transplant medicine.